During the past decade, macrophage-derived substances such as prostanoids, cytokines, growth factors and angiogenic factors have been detected in the peritoneal fluid of women with endometriosis. In particular, growth-promoting and angiogenic factors are considered to be substantially involved in the pathogenesis of endometriosis. In this study, vascular endothelial growth factor (VEGF), transforming growth factor β (TGF-β) and intercellular adhesion molecule 1 (ICAM-1), substances recently detected in the peritoneal fluid of women with endometriosis, were assessed with regard to their concentrations in different stages of endometriosis and changes of the peritoneal paracrine activity after medical treatment with a gonadotrophin releasing hormone agonist (GnRHa). Peritoneal fluid was obtained from patients with endometriosis during laparoscopy before and after a 4-month treatment with a GnRHa. VEGF, TGF-β and ICAM-1 could be detected in all women presenting with various stages of active endometriosis. After GnRHa therapy, all patients showed significant decreases in mean concentrations of VEGF (194 ± 77 pg/ml), TGF-β (902 ± 273 pg/ml) and ICAM-1 (157 ± 52 ng/ml). Patients with stage III and IV endometriosis (according to the rAFS score) had much higher concentrations of VEGF and TGF-β before treatment compared with those patients with mild endometriosis (rAFS stages I and II). The most striking decrease in concentration was for TGF-β, from 902 pg/ml before to 273 pg/ml after therapy. These results indicate an important role for paracrine activity in the establishment and maintenance of endometriosis. Indeed, treatment with a GnRHa may reduce paracrine activity in the peritoneal cavity via hypo-oestrogenism and provide proof of successful therapy.
Introduction
In the past 10 years, it has been demonstrated that the volume of peritoneal fluid is increased in women with endometriosis, indicating an alteration of the peritoneal environment. Moreover, peritoneal fluid of such women contained a much higher concentration of macrophages and monocytes (Halme et al., 1983) which are responsible for the secretion of a variety of substances such as cytokines, prostaglandins and growth factors. These substances are assumed to be involved in the pathogenetic cascade of this disease. Increased peritoneal vascularization, endometriotic implants and adhesion formation are the most striking signs of the pathomorphology of endometriosis. Thus, it could be claimed that vascular endothelial growth factor (VEGF), a heparin-binding angiogenetic growth factor of 30-40 kDa, a mediator of neovascularization (Connolly et al., 1989; Ferrara et al., 1992) , transforming growth factor β (TGFβ), a 25 kDa protein known to stimulate macrophages, fibroblasts and collagen production (Massague et al., 1990) , and intercellular adhesion molecule 1 (ICAM-1), a 90 kDa glycoprotein (Rothlein et al., 1986; Seth et al., 1991) , are all promoters of growth and adhesion formation and involved in the pathogenesis of endometriosis.
The objective of the present study was to evaluate the pathogenetic implications of these peritoneal fluid components by assaying their concentrations before and after 4 months' gonadotrophin releasing hormone agonist (GnRHa) therapy.
Paracrines, peritoneal fluid and endometriosis
Twenty women presenting with different stages of endometriosis diagnosed at laparoscopy were included in this study. The women were referred to hospital for infertility or severe dysmenorrhoea/dyspareunia. Stages of endometriosis were categorized according to rAFS score (AFS, 1997) and the characteristics of activity or inactivity of the endometriotic lesions. All patients underwent a 4-month treatment with Decapeptyl-Gyn-Depot® (Ferring Pharmaceuticals, Kiel, Germany) with subsequent secondlook laparoscopy. Written consent was obtained from all patients participating in the study. Peritoneal fluid was collected at laparoscopy under direct visual control from the posterior cul-de-sac through a second puncture. Aspiration was carried out before any surgical manipulation and before the patient was placed into the Trendelenburg position in order to obtain all fluid in the peritoneal cavity. The fluid samples were immediately placed into tubes and centrifuged at 2000 g for 5 min at +4°C and then stored at -70°C. Concentrations of VEGF, TGF-β and ICAM-1 were measured in the peritoneal fluid collected at laparoscopy before and after medical treatment using a commercially available enzyme-linked immunosorbent assay (ELISA; Biermann Company, Bad Nauheim, Germany). In addition, CA-125 was measured in the peripheral blood before and after treatment. Peritoneal fluid from 20 healthy normal cycling women served as a control.
Statistical analyses were performed using the WilcoxonRank test. A P-value of <0.005 was considered significant. Table I . Paracrine activity in peritoneal fluid before and after gonadotrophin releasing hormone agonist therapy (Decapeptyl-Gyn-Depot®) in endometriosis patients (n =20) and controls (n = 20) VEGF, TGF-β and ICAM-1 were detected in the peritoneal fluid of all women presenting with various stages of active endometriosis After GnRHa therapy, all patients showed a significant decrease in mean concentra- tions of VEGF (194 ± 77 pg/ml), TGF-β (902 ± 273 pg/ml) and ICAM-1 (157 ± 52 ng/ml) (Table I ) and a significant reduction in the volume of peritoneal fluid. Patients with stage III and IV endometriosis according to the rAFS score displayed much higher concentrations of VEGF and TGF-β before treatment compared with those patients with minor lesions of the peritoneal mesothelium (rAFS stages I and II) ( Table II) . The most striking decrease in concentration was seen for TGF-β, from 902 pg/ml before to 273 pg/ml after medical therapy. All patients with stage I, II and stage III endometriosis showed a significant reduction in endometriotic lesions (Figures 1 and 2) after therapy, while patients with severe (stage IV) endometriosis showed no improvement in their endometriotic pathomorphology. However, in contrast to this clinical finding, even these patients had significantly lower peritoneal fluid concentrations of VEGF, TGF-β and ICAM-1 after therapy. Pain patients and infertility patients showed no statistically significant differences in concentrations of VEGF, TGF-β and ICAM-1 (Table III) , indicating that no link could be established between either infertility or dysmenorrhoea/dyspareunia with regard to paracrine activity in the peritoneal cavity. Serum concentrations of CA-125 also decreased after therapy. In the control group of normal-cycling healthy fertile young women, concentrations of all parameters were statistically significantly lower than in the endometriosis group. 
The peritoneal environment in endometriosis
In the past decade, evidence has accumulated to document the presence of inflammatory reactions in the peritoneal cavity of women with endometriosis (Haney et al., 1991) . A number of studies have shown the presence of macrophage-derived substances and demonstrated their activity in the peritoneal fluid of such women. Increased concentrations of prostaglandins, cytokines such as interleukin (IL) -1, IL-2, IL-6, IL-8 and tumour necrosis factor α (TNF-α), and factors including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), endothelial growth factor (EGF), TGF-α and -β, macrophage colony stimulating factor (MCSF), insulin-like growth factor (IGF) and IGFBP were also detected (Ramey and Archer, 1993) (Figure 3 ). Increased vascularity on the peritoneal mesothelium and in and around endometriotic lesions is a well-known phenomenon and indicates the onset of angiogenesis, confirmed by the identification of angiogenic factors in the peritoneal fluid. Angiogenesis appears to be of major importance in the establishment of the disease. VEGF and angiogenin have been detected in the peritoneal cavity of women with endometriosis. McLaren et al. (1996) demonstrated that fluid from such patients contained significantly greater amounts of VEGF than controls. Oosterlynck et al. (1993) assayed and proved the angiogenic capacity of peritoneal fluid from patients with endometriosis in vitro using the chicken embryo chorioallantoic membrane (CAM) model. TGF-β and IL-8 (Chegini et al., 1994; Ryan et al., 1995) are apparently involved in the communication and modification of cellular interactions. Their autocrine and paracrine effects provide mitogenic stimuli for fibroblasts, leading to adhesion formation and support maintenance of viable endometriotic tissue. Furthermore, TGF-β also exhibits angiogenic activity, as described by Folkman and Klagsbrun (1987) . TNF-α and interferon-γ have been implicated in sperm and embryo toxicity and are thus mediators of unexplained infertility often associated with milder forms of endometriosis, as hypothesized by Taketani et al. (1992) . ICAM-1 has been characterized as essential for various immunological functions and for the control of cell-cell adhesion (Somigliana et al., 1996) . It has been shown that the release of ICAM-1 may allow endometrial cells to escape immunosurveillance, in particular in association with the activity of natural killer cells.
This study clearly confirmed the findings of peritoneal fluid activity in women with endometriosis, and indicated the involvement of growth-and adhesion-promoting substances such as TGF-β and ICAM-1. As a predominant angiogenic factor, VEGF appears to play a key role in the pathogenic pathway of initiating endometriosis. The severity and activity of the disease is significantly reflected in the concentration of those factors, whereas no difference in concentration could be detected with regard to pain or infertility.
Medical treatment of endometriosis with GnRHa is known to be successful in terms of reducing endometriotic lesions and pain via hypo-oestrogenism. In the present study, the surprising impact of hypo-oestrogenism on those immunogenetic macrophage-derived factors affecting the peritoneal environment to establish endometriosis has been demonstrated. Peritoneal fluid concentrations of VEGF, TGF-β and ICAM-1 were significantly reduced after 4-months' therapy in all cases. Second-look laparoscopy revealed no visible endometriotic lesions in the peritoneal cavity in cases of mild or moderate endometriosis (rAFS stages I-III), whereas in cases of severe endometriosis (rAFS stage IV) the clinical appearance appeared to show no change in the disease. Symptoms of pain disappeared in all cases during medical treatment, while four patients with mild or moderate endometriosis diagnosed at first laparoscopy conceived within 6 months of a second laparoscopy.
Conclusion
Growth factors such as VEGF, TGF-β and ICAM-1 were detected in significantly higher concentrations in the peritoneal fluid of women with endometriosis than in normal healthy women. This suggests the presence of paracrine control mechanisms in the pathogenesis of this disease. GnRHa therapy led to clinical improvement and a significant decrease in concentrations of these growth factors, and a positive correlation between concentrations of growth factors and the disease severity of endometriosis was established. However, whether immunogenetic activity in the peritoneal cavity is an epiphenomenon or plays a key role in the evolution to establish endometriosis remains to be clarified.
